| Name | Title | Contact Details |
|---|
STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.
Biodyne Inc is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
PaxVax is a privately held, fully integrated vaccine company, based in Redwood City, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact. Our founding principles were to enable geographically distributed manufacturing of affordable, self-administered oral vaccines against infectious diseases such as influenza. Since then, we have expanded our capabilities and technologies to address unmet vaccine needs against endemic diseases in developing countries, for travelers to disease-laden areas and in biodefense. Our clinical stage portfolio today includes vaccine candidates for cholera, avian influenza (H5N1), anthrax, and HIV. We are committed to providing both attractive financial returns and social returns, without a significant trade-off between the two. As a double bottom line business, we will measure our financial success in terms of return on equity and we will assess our social returns by access to our vaccines globally, particularly to the poor and otherwise disenfranchised. We strive to develop and deliver vaccines that are affordable and deliverable anywhere in the world regardless of the state of medical infrastructure or supply chains. We utilize investment capital as well as R&D grants and contracts to fund the development of our vaccines. We exploit the inherent synergies in our proprietary oral vaccine technology platform to research and develop multiple vaccine candidates in a timely and capital efficient manner. We strive to make an impact on infectious disease morbidity and mortality throughout the world and on the global vaccine industry through our successes. To date, we have raised more than $75 million (USD) from investors including Ignition Ventures, Ignition Growth and the Wellcome Trust. We are supported by R&D grants and contracts from the U.S. National Institutes of Health (NIH) through both its National Institutes of Allergy and Infectious Diseases (NIAID) and Division of AIDS (DAIDS) as well as the Bill & Melinda Gates Foundation. Our most advanced vaccine is a single dose oral cholera vaccine, which entered final or Phase III clinical trials, and whose study should be completed in 2014. Following this candidate is a vaccine ready for Phase II (Pandemic Influenza), two caccines in current Phase I studies (HIV and anthrax), and multiple candidates in preclinical research (HSV, dengue, malaria). PaxVax is headquartered in Redwood City, California and is incorporated in Delaware. Our laboratory and manufacturing facilities and the majority of our 80 employees are located in San Diego, California.